Anzeige
Mehr »
Login
Dienstag, 21.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News! 22 Jahre "BlueChip"-Power nun bei NurExone!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PU3T | ISIN: US81642T2096 | Ticker-Symbol: RXK3
Tradegate
20.05.24
09:27 Uhr
1,360 Euro
+0,020
+1,49 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SELLAS LIFE SCIENCES GROUP INC Chart 1 Jahr
5-Tage-Chart
SELLAS LIFE SCIENCES GROUP INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,3301,39020.05.
1,3421,37620.05.

Aktuelle News zur SELLAS LIFE SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.05.SELLAS Life Sciences GAAP EPS of -$0.215
14.05.SELLAS Life Sciences Group, Inc. - 8-K, Current Report3
01.05.SELLAS Reports Positive Phase 2 Preliminary Data With SLS0093
01.05.SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level35- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential - - 100% Overall Response...
► Artikel lesen
29.04.SELLAS Life Sciences announces IDMC's recommendation of continuing REGAL phase 3 study without modifications8
29.04.SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study115- Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Patients Treatment and Follow-Up Without Any Modifications...
► Artikel lesen
28.03.Sellas Life Sciences Group Inc reports results for the quarter ended in December - Earnings Summary6
28.03.SELLAS Life Sciences Group files for $200M mixed shelf4
28.03.SELLAS Life Sciences GAAP EPS of -$1.34 misses by $0.243
28.03.SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update120Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified Biomarkers...
► Artikel lesen
28.03.SELLAS Life Sciences Group, Inc. - 8-K, Current Report3
26.03.SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study551- Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April - - Phase 2a study of SLS009 in r/r AML: 50% Response...
► Artikel lesen
19.03.SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules12
19.03.SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET9
15.03.SELLAS Life Sciences Group, Inc. - 8-K, Current Report 8
15.03.SELLAS Life Sciences secures $20 million in stock and warrant offering10
15.03.Sellas Announces $20 Mln Registered Direct Offering, Concurrent Private Placement9
15.03.SELLAS Life Sciences looks to raise $20M in a direct offering8
15.03.SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules10
08.03.Sellas sends 2 execs packing while awaiting phase 3 cancer vax readout19
Seite:  Weiter >>
62 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,5